摘要
近年来,在B细胞淋巴瘤治疗领域围绕B细胞受体信号传导通路涌现出众多生物药物及小分子药物,这些药物在复发/难治B细胞淋巴瘤中取得了很好的疗效。本文对上述药物的最新临床研究结果进行总结,并探索其在初治B细胞淋巴瘤中的应用价值。
In recent years,many biological and small molecule drugs have emerged in the field of B-cell lymphoma treatment around BCR signal transduction pathway.These drugs have achieved good results in the treatment of relapsed or refractory B-cell lymphoma.This article summarizes the latest clinical studies of these drugs,and explores the value of these drugs in the initial treatment of B-cell lymphoma.
作者
吴梦
宋玉琴
朱军
WU Meng;SONG Yu-qin;ZHU Jun(Department of Lymphoma,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),Peking University Cancer Hospital & Institute,Beijing 100142,China)
出处
《中国医学前沿杂志（电子版）》
2018年第12期15-19,共5页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家自然科学基金(81870154
81470368
81670187
81600164)
北京市自然科学基金(7172047
7172046)
首都卫生发展科研专项(2018-1-2151)
北京市医管局"登峰"计划(DFL20151001)
北京市医管局培育计划(No.PX2017001)
北京医卫健康公益基金会(2221-16-157)
